This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biogen Inc (BIIB)

NASDAQ: Health Care

Company Cash Flow
Dec 2015 Dec 2014 Dec 2013 Dec 2012
Cash Flow From Operating Activities
Net Income (Loss) 3.59B 2.94B 1.86B 1.38B
Operating Gains/Losses 0.00 0.00 0.00 0.00
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables 29.00M -512.39M -126.75M 3.57M
(Increase) Decrease in Inventories -174.40M -185.92M -243.96M -140.31M
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 -39.67M
(Decrease) Increase In Payables 0.00 0.00 0.00 0.00
(Decrease) Increase In Other Current Liabilities -242.40M 339.16M 602.56M 307.48M
(Increase) Decrease In Other Working Capital -187.70M -125.21M -144.46M -27.35M
Other Non-Cash Items 243.60M 104.98M 108.68M 147.39M
Net Cash From Continuing Operations 3.72B 2.94B 2.35B 1.88B
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 3.72B 2.94B 2.35B 1.88B
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -643.00M -287.75M -3.51B -261.18M
Acquisitions -1.05B -375.00M -15.00M -72.40M
Purchases of Short-Term Investments 0.00 0.00 0.00 0.00
Other Cash from Investing Activities -59.90M -16.00M 7.37M 2.75B
Cash Provided by Financing Activities
Net Cash From Investing Activities -4.55B -1.54B -1.60B -950.34M
Issuance of Debt 5.93B 0.00 0.00 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 54.20M 54.89M 66.77M 67.49M
Repayment of Long-Term Debt -2.10M -2.67M -452.34M -2.43M
Repurchase of Capital Stock -5.00B -886.78M -400.31M -984.72M
Payment of Cash Dividends 0.00 0.00 0.00 -2.73M
Other Financing Charges, Net 3.80M 78.69M 69.35M 44.90M
Net Cash From Financing Activities 986.40M -755.87M -716.53M -877.48M
Effect of Exchange Rate Changes -45.80M -40.90M 7.96M 4.10M
Net Change in Cash & Cash Equivalents 103.10M 602.36M 31.84M 56.18M

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

Analysts Ratings for BIIB

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 10 10 10 11
Moderate Buy 2 2 2 2
Hold 8 8 8 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

BIIB Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs